Vyant Bio (VYNT) Reports Q1 Loss from Cont. Operations of $0.15
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Wall St set for higher open as Anthropic's IPO filing sharpens AI focus
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
Tweet
Share
E-mailGet Alerts VYNT Hot Sheet
Join SI Premium – FREE
Vyant Bio (NASDAQ: VYNT) reported Q1 EPS from continuing operations of ($0.15), versus the consensus of ($0.16). Revenue for the quarter came in at $303 thousand versus the consensus estimate of $300 thousand.
Cash and cash equivalents totaled $16.4 million as of March 31, 2022.
For earnings history and earnings-related data on Vyant Bio (VYNT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ponce Financial Group, Inc. (PDLB) Tops Q3 EPS by 24c
- New Street Research Upgrades Intel (INTC) to Buy
- New survey reveals Wall Street's consensus S&P 500 targets for end of 2026
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
